GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Insider Ownership

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Insider Ownership : 5.75 % (As of Jun. 04, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Telomir Pharmaceuticals's insider ownership is 5.75%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Telomir Pharmaceuticals's Institutional Ownership is 0.03%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Telomir Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 56.44%.


Telomir Pharmaceuticals Insider Ownership Historical Data

The historical data trend for Telomir Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Insider Ownership Chart

Telomir Pharmaceuticals Historical Data

The historical data trend for Telomir Pharmaceuticals can be seen below:

2024-02-29 2024-03-31 2024-04-30
Insider Ownership 5.75 5.75 5.75

Telomir Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines